Rotavirus in New Zealand 2016

Saturday 29th January 2022


A marked decrease in rotavirus hospitalisations and community infections has occurred in children under 5 years since the oral rotavirus vaccine RotaTeq® was added to the national immunisation schedule on 1 July 2014. This report presents information on rotavirus infections in 2016 from a variety of sources, including national hospital discharges, sentinel hospital-based surveillance and genotyping of rotavirus-positive samples from community and hospital laboratories.

In the two years following the introduction of rotavirus vaccine, there was an 88.7% decrease in the rate of rotavirus hospitalisations for children aged under 5 years compared with the previous five-year average (2010–2014). Socioeconomic disparities remain, with statistically significant higher rotavirus hospitalisation rates in children aged under 5 years in deprivation quintiles 4 and 5, compared with those in quintile 1.

G12P[8] was the predominant (55.4%) rotavirus genotype detected in 2016, and G2P[4] was the second most common (19.1%). Four samples were confirmed as containing a component of the RotaTeq® vaccine, including two from unvaccinated cases.

In July 2017, the rotavirus vaccine on the national immunisation schedule was changed to Rotarix®. Continued rotavirus surveillance will be important to monitor trends in severe rotavirus infection and vaccine selection pressure on rotavirus genotypes.

Note: Click on the document links below to open. These documents are in PDF format. You will need to download the free Adobe Acrobat Reader to view them.


Rotavirus in New Zealand 2016



Rotavirus in New Zealand 2016

Ph: +64 4 914 0700 Fax: +64 4 914 0770 Email: